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report interactions, however, generated 1,370 alerts (aver-
age 4.5 alerts/patient). Only 147 (11%) drug-drug interaction 
alerts were identical to those identified by manual checking; 
the remaining 89% were considered not clinically relevant. 
 Conclusions: Compared to identification of DRPs by clinical 
pharmacologists, the clinical decision support software per-
formed poorly due to over-alerting and inability to assess for 
problems not caused by drug-drug interactions. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Computerized physician order entry (CPOE) is be-
coming more widespread in the care of cardiovascular 
surgery inpatients. While CPOE is associated with a
reduction in drug-prescribing errors  [1] – primarily 
through prevention of misinterpretation of handwritten 
prescriptions – new problems related to the electronic 
nature of drug prescribing itself have emerged with time 
 [2] . Furthermore, CPOE cannot prevent drug-related 
problems (DRPs) which arise, for example, due to con-
current morbidities, renal or hepatic dysfunction, or 
drug-drug interactions. Clinical pharmacology and/or 
clinical pharmacy services can provide valuable input in 
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 Abstract 
 Objectives: Drug-related problems (DRPs) are events or cir-
cumstances involving drug therapy that actually or poten-
tially interfere with desired health outcomes. This study test-
ed the applicability of clinical decision support software in 
identifying and managing DRPs among cardiovascular sur-
gery inpatients.  Methods: Two clinical pharmacologists at-
tended ward rounds on a low-dependency cardiovascular 
surgery ward every 2 weeks over a 7-month period. Three 
hundred and three patients were assessed. On average, pa-
tients received 17 scheduled and ‘as required’ medicines. 
DRPs were identified ‘manually’ via assessment of electronic 
prescription charts and patient records and ‘electronically’ 
using clinical decision support software (Pharmavista  ). The 
numbers of alerts for optimizing medication safety gener-
ated by the two methods were compared.  Results: Manual 
checking identified 346 DRPs leading to 346 alerts in 201 pa-
tients (overall 1.1 alerts/patient). Relevant interactions ac-
counted for 44% of DRPs detected by clinical pharmacolo-
gists. Clinical decision support software, which could only 
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identifying DRPs and providing suggestions as to how 
they might be avoided. Such services, however, are labor- 
intensive and costly. An alternative is the use of clinical 
decision support software (CDSS) which can be integrat-
ed into the electronic prescribing process. However, the 
applicability of such a system in the care of cardiovascu-
lar surgery inpatients is not known. The purpose of this 
study was to determine the applicability of a simple com-
puterized decision support system which assessed for 
drug-drug interactions (the commonest type of CDSS in 
Europe) in a group of such patients by comparing its per-
formance with that of clinical pharmacologists in iden-
tifying DRPs.
 Methods and Materials 
 Ward rounds of pre- and postoperative cardiovascular surgery 
patients were attended every second week by two clinical pharma-
cologists over a 7-month period from November 2010 to June 
2011. This study period was chosen because the treating surgeons 
and physicians did not change during this time. The setting was 
a ward without intensive care or high-dependency beds. All pa-
tients were cared for using integrated electronic medical records 
(with electronic prescribing). An additional feature of the elec-
tronic prescription chart was the electronic drug interaction 
check CDSS supplied by Pharmavista  (e-mediat AG, Bern, Swit-
zerland)  [3] . When requested to do so by the prescriber, this pro-
gram assessed potential drug-drug interactions and graded these 
according to the required intervention (based on the operational 
classification of drug interactions by Hansten et al.  [4] ). The CDSS 
did not flag up potential problems automatically. Such alerts are 
known as ‘noninterruptive’ alerts and differ from ‘interruptive’ 
alerts which require acknowledgement from the prescriber of the 
awareness of the DRP usually in the form of a mouse click. It was 
not known how often the interaction check software was used by 
the prescribing surgeons. Other than the voluntary drug interac-
tion check, no electronic clinical decision support (regarding dos-
ing, for example) was embodied in the electronic prescription 
chart.
 Clinical pharmacologists assessed the electronic prescription 
charts for the presence of drug-related issues. Internet-based da-
tabases including Swiss, German, and US product information, 
PubMed, the Pharmavista  tool  [3] , and the Micromedex  
Healthcare Series (Thomson Reuters, Greenwood Village, Col., 
USA)  [5] were used.
 DRPs were defined according to the Pharmaceutical Care Net-
work Europe (PCNE) classification for drug-related problems, 
version 6.2 (revised on January 14, 2010), which defines a DRP as 
‘an event or circumstance involving drug therapy that actually or 
potentially interferes with desired health outcomes’  [6] . Drug-re-
lated issues included all DRPs and instances where specific infor-
mation regarding drug therapy (such as the pharmacokinetics of 
intravenously or orally administered antibiotics) was requested 
by the treating surgeons. Proposals for optimizing drug safety 
were then given to the treating surgeons face-to-face on the ward 
round.
 For the purposes of analysis, DRPs were classified according 
to a simplified PCNE system which defined the drug-related is-
sues as a lack of treatment effect (P1 of PCNE version 6.2), an ad-
verse drug event (P2), and provision of information. Underlying 
causes of a lack of treatment effect or an adverse drug event were 
classified as resulting from an interaction (C1.3), inappropriate 
dosing (C3), contraindication (C1.1), inappropriate timing of ad-
ministration (C5.1), inappropriate duplication of therapeutic 
group or active ingredient (C1.4), unclear prescription (including 
problems arising from electronic prescribing) (C6.2), need for 
therapeutic drug monitoring (C3.5), known side effect of the 
drug, and failure to correctly document drug allergies and subop-
timal choice of drug form (C2.1) or drug (C1.1).
 Data are presented as numbers and percentages. The average 
number of drugs prescribed per patient was determined from a 
randomly selected subgroup of 30 patients. Similarly, data on the 
number of drug prescriptions which CDSS was unable to recog-
nize was collected for 7 ward rounds and used to estimate the 
overall percentage of drug prescriptions which could not be in-
cluded in the automated analysis for drug-drug interactions. A 
positive predictive value calculation was performed using clinical 
pharmacologists’ judgments as the gold standard.
 Results 
 The electronic prescription charts of 303 patients were 
assessed. On average, each patient had 17 different medi-
cations prescribed on a regular and ‘as required’ basis. Of 
these prescriptions, approximately 4.5% could not be rec-
ognized by CDSS as they had been entered into the elec-
tronic drug chart as ‘free text’ fields.
 The types and frequencies of drug-related issues are 
shown in  table 1 . Potential adverse drug events were the 
most common (72%), followed by potential lack of treat-
ment effect (15%), actual adverse drug events (6%) and 
provision of information pertaining to drug prescrip-
tions as requested by the treating surgeons (4%). Drug-
drug interactions were the underlying cause of 153 DRPs 
(44% of all DRPs). The 5 most common drug-drug inter-
actions were paracetamol in combination with an en-
zyme inducer (such as rifampicin or phenytoin, n = 9), the 
combination of rifampicin and an opiate analgesic (n = 
7), the combination of polyvalent cations with fluoroqui-
nolones (n = 6) or levothyroxine (n = 6), and the combi-
nation of amiodarone with statins (n = 5). Formally con-
traindicated drug-drug combinations were the combina-
tion of amiodarone with domperidone, an antiemetic 
associated with QTc prolongation (n = 4). These latter 
cases, however, did not cause any manifest adverse drug 
events.
 CDSS identified 147 of these 153 interactions, in addi-
tion to reporting on an additional 1,223 interactions 
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which were not judged clinically relevant by the clinical 
pharmacologists ( fig.  1 ). In addition to this ‘over-alert-
ing’, whereby only 11% of computer-generated alerts were 
clinically applicable, 61% of all drug-related issues could 
not be identified by this form of CDSS, therefore repre-
senting a simultaneous gross ‘under-alerting’. The posi-
tive predictive value of CDSS for interactions was 0.107 
when considering clinical pharmacologists’ judgments to 
be the ‘gold standard’.
 A small but relevant number of DRPs were related to 
the CPOE system itself (n = 9), as shown in the footnote 
to  table 1 .
 Discussion 
 While the incidence of DRPs in this group of cardio-
vascular surgery inpatients was less than that found in 
other studies of hospitalized patients  [7] , drug-drug in-
teractions were the underlying cause for the majority of 
the detected DRPs. This was higher than found in a pre-
vious study of medical inpatients at the same hospital 
(33%)  [8] and likely reflects the more frequent use of 
drugs such as amiodarone and rifampicin in our patient 
population. While CDSS was able to detect nearly all of 
the drug-drug interactions seen by clinical pharmacolo-
gists, it also generated a large number of over-alerts (89% 
of CDSS-generated alerts were not judged to be clini-
cally relevant) in addition to being unable to alert on 
dosing adaptation, drug allergies, and other contraindi-
cations.
 The implications of these findings are threefold. First, 
in order to be clinically applicable, CDSS should be opti-
mized to detect all relevant DRPs. Such systems are, how-
ever, expensive and still under development. Secondly, we 
found a failure to detect all clinically relevant drug-drug 
Table 1.  Drug-related issues (n = 359, of which 346 were DRPs) 
and, where applicable, their underlying causes in 303 cardiovas-
cular surgery inpatients
Drug-related issue/
underlying cause
Number
(% of total)
Number
identified
by CDSSa
Lack of treatment effect 0 0
Adverse drug event
Known side effect of drug 21 (5.8)b 0
Interaction 1 (0.3) 1 (0.3/0.1)
Potential lack of treatment effect
Interaction 44 (12.2) 40 (11.1/2.9)
Inappropriate dose 9 (2.5)c 0
Time of administration 1 (0.3) 0
Potential adverse drug event
Known side effect of drug 33 (9.1) 0
Interaction 104 (29.0) 102 (28.4/7.4)
Time of administration 5 (1.4) 0
Drug choiced 17 (4.7) 0
Inappropriate dose 45 (12.5)e 0
Contraindication 28 (7.8) 4 (1.1/0.3)
Need for therapeutic
drug monitoring 3 (0.8) 0
Prescription unclear 11 (3.0) 0
Duplication of therapeutic class 15 (4.2) 0
Documentation of allergies 7 (1.9)f 0
Information given 15 (4.2) 0
a  % of all drug-related issues/% of total interactions found by 
CDSS (n = 1,370).
b Two adverse drug events reported to the authorities (one case 
of paradoxical reaction to lorazepam and one case of levodopa 
withdrawal symptoms). 
c Seven due to incorrect prescription of low-molecular-weight 
heparin as 1 unit instead of 1 prefilled syringe – a problem facili-
tated by the electronic prescribing process. 
d Two due to incorrect prescription of apomorphine instead of 
morphine for analgesia – a problem facilitated by the electronic 
prescribing process per se. 
e Fifteen instances where dosing exceeded the maximum li-
censed dose and 5 instances where dose adjustment for intermit-
tent hemodialysis was indicated; the remainder was due to im-
paired renal or hepatic function and in response to therapeutic 
drug monitoring results. 
f One instance where a drug was administered despite the
patient having a documented allergy; however, no adverse drug 
event occurred.
1,223 147 212
CP (359)
CDSS (1,370)
 Fig. 1. Area-proportional Venn diagram of alerts generated by the 
CDSS and by clinical pharmacologists (CP). Figures are absolute 
numbers. 
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interactions despite the large number of alerts generated 
by CDSS. In this study, the reasons why CDSS was unable 
to identify 6 relevant drug-drug interactions were an in-
ability to recognize drug prescriptions entered as ‘free 
text’ (and not chosen from drop-down menus) and the 
exceeding of the CDSS’s computational capacity in one 
case. These limitations of CDSS should be addressed and 
eliminated in future software development. Thirdly, the 
large number of over-alerts seen in this and other studies 
 [9, 10] is cause for concern as clinicians are more likely to 
ignore all alerts when only 1 out of 10 alerts is relevant, 
thereby deriving no benefit for their patients from the 
CDSS. In the recent study of CDSS-generated drug-drug 
interaction alerts by Seidling et al.  [9] , only 1.4% of non-
interruptive alerts were accepted. For ‘interruptive’ alerts 
the authors identified the frequency of the alert, the qual-
ity of the message displayed, the alert level, and the con-
textual setting (e.g. inpatients and prescriptions involv-
ing drugs with dose-dependent toxicity) as being associ-
ated with increased acceptance  [9] .
 The present study has limitations. The judgments of 
the two clinical pharmacologists were taken as the ‘gold 
standard’ for the purposes of determining the perfor-
mance of CDSS in this setting but they may have been 
incomplete or biased. However, there are no established 
‘gold standards’ in this field. For a simple 10-category sys-
tem for classifying DRPs, the inter-rater agreement was 
found to be 0.68  [11] . The CDSS system used here is one 
which is more widespread in Europe than in the USA, 
where systems capable of alerting on DRPs not solely aris-
ing from drug-drug interactions are commonly in place. 
Whether the findings of our study are more widely ap-
plicable to other patient settings, other clinical pharma-
cology and clinical pharmacist services, and other pre-
scribers merits further study.
 Conclusions 
 Taken together, our findings show that drug-drug in-
teraction CDSS in its current form is unlikely to be of as-
sistance to surgeons treating cardiovascular surgery in-
patients due to a combination of over-alerting and the 
high number and complexity of DRPs which go beyond 
drug-drug interactions. Monitoring of the prescribed 
drug regimen by a clinical pharmacologist remains an 
important measure towards optimizing medication safe-
ty in cardiovascular surgery patients until both CPOE 
and CDSS are optimized.
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